Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;52(1):21-31.
doi: 10.3906/sag-2106-63. Epub 2022 Feb 22.

SARS-COV-2 vaccine: first-month results of a six-month follow-up study

Burak Mete  1 , Ferdi Tanır  1 , Hakan Demirhindi  1 , Ertan Kara  1 , Filiz Kibar  2 , Salih Çetiner  3 , Aslıhan Candevir  4 , Rabia Dal  1
Affiliations

SARS-COV-2 vaccine: first-month results of a six-month follow-up study

Burak Mete et al. Turk J Med Sci. 2022 Feb.

Abstract

Background: Various COVID-19 vaccines are being developed around the world. Important questions to be answered regarding vaccines are efficacy, safety, and whether antibodies are protective when used in different communities. This study aimed to determine seroconversion rates of the inactivated SARS-CoV-2 vaccine in healthcare workers in a hospital and short-term adverse events due to the vaccine.

Methods: The study carried out in Çukurova University, Turkey, comprised of 282 healthcare workers who received two doses of the inactivated SARS-CoV-2 vaccine administered in two 3 µg doses, 28 days apart. On day 28, after the second dose, antiS-RBD IgG and total anti-spike and anti-nucleocapsid IgM and IgG antibodies against SARS-CoV-2 were detected by using in vitro chemiluminescence immunoassay method.

Results: The mean age of participants was 39.06±10.65 (min=21, max=65) with 43.6% males and 56.4% females. On day 28, after the second dose, the seroconversion rates were found to be 92.9% for total anti-spike and anti-nucleocapsid IgG and 15.2% for IgM and 98.2% for anti-S-RBD IgG antibodies and having natural COVID-19 prior to vaccination, age and comorbidity were found to be significant factors for immunogenicity. The incidence of at least one adverse event was found as 29.8% after the first dose and 24.1% after the second dose, with the most common adverse events of having pain at the injection site, weakness, fatigue, and headache.

Keywords: SARS-COV-2; adverse events; immunisation; seroconversion; vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Anti-S RBD IgG (AU/mL) and total anti-spike and anti-nucleocapsid IgG (AU/mL) concentrations according to the history of COVID-19 prior to vaccination *Yes: The participant had a history of natural COVID-19 prior to vaccination *No: The participant did not have a history of natural COVID-19 prior to vaccination
Figure 2
Figure 2
Anti-S RBD IgG (AU/mL) and total anti-spike and anti-nucleocapsid IgG (AU/mL) concentrations according to the age groups (including all participants)
See this image and copyright information in PMC

References

    1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–473. doi: 10.1016/S0140-6736(20)30185-9. - DOI - PMC - PubMed
    1. Arvin AM, Greenberg HB. New viral vaccines. Virology. 2006;344(1):240–249. doi: 10.1016/j.virol.2005.09.057. - DOI - PubMed
    1. Lee S, Nguyen MT. Recent Advances of Vaccine Adjuvants for Infectious Diseases. Immune Netwok. 2015;15:51–57. doi: 10.4110/in.2015.15.2.51. - DOI - PMC - PubMed
    1. Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, et al. Synthetic DNA vaccines: improved vaccine potency by electroporation anc co-delivered genetic adjuvants. Frontiers in immunology. 2013;4:354. doi: 10.3389/fimmu.2013.00354. - DOI - PMC - PubMed
    1. Gao Q, Bao LL, Mao HY, Wang L, Xu KW, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77–81. doi: 10.1126/science.abc1932. - DOI - PMC - PubMed